Formycon Reveals Keytruda Biosimilar In The Works
A Formulation Patent Is Pending While Manufacturing Capacity Has Been Secured
Executive Summary
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.